Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 4/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852531 | 0.80 | AXL (0.58) | GRM4SIGMAR1KITAXLEGFR | |
| SCHEMBL31428805 | 0.77 | GRM2 (0.49) | GRM4ADORA2ABRD4EPHX2GRM2 | |
| SCHEMBL24975833 | 0.77 | GRM2 (0.49) | GRM4ADORA2ABRD4EPHX2GRM2 | |
| SCHEMBL17673264 | 0.75 | AXL (0.47) | BRD4EPHX2HRH4AXLPIM1 | |
| SCHEMBL17942667 | 0.75 | BRD4 (0.47) | BRD4PRMT5GRM2AXLPIM1 | |
| SCHEMBL29848857 | 0.75 | AXL (0.47) | BRD4EPHX2HRH4AXLPIM1 | |
| SCHEMBL355762 | 0.75 | GRM4 (0.65) | GRM4BRD4GRM2AURKBACVR1 | |
| SCHEMBL31428975 | 0.75 | GRM4 (0.65) | GRM4BRD4GRM2AURKBACVR1 | |
| SCHEMBL31469381 | 0.74 | AURKB (0.49) | BRD4KITAXLAURKB | |
| SCHEMBL31469361 | 0.74 | AURKB (0.49) | KITAXLAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | GRM4 4341/4885ADORA2A 3904/4885BRD4 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.